Last edition
News about "biopharmaceutical company "
Chiesi Group Expands Partnership with Bespak to Scale Up Low-Carbon Inhaler Manufacturing
Chiesi Group and Bespak have expanded their partnership to boost pMDI manufacturing capacity in the UK, supporting the rollout of next-generation Carbon Minimal Inhalers designed to significantly reduce environmental impact.
Biopharmaceutical Company | 13/03/2026 | By News Bureau | 106
XYRA receives a US patent protecting dose-adjusted budiodarone therapy for atrial fibrillation, aiming to reduce stroke and heart failure risk through patient monitoring while offering a safer rhythm-control option.
Biopharmaceutical Company | 06/03/2026 | By News Bureau
Frontier Biotechnologies Inc. Signs USD 1 Billion siRNA Licensing Deal with GSK
Frontier Biotech has granted GSK exclusive global rights to two siRNA drug candidates in a deal worth up to USD 1 billion, strengthening its international expansion and immunology pipeline focus.
Biopharmaceutical Company | 25/02/2026 | By News Bureau | 148
Sanofi Announces Euro 1 Billion Share Buyback Programme for 2026
R&D-driven biopharma major Sanofi to repurchase shares worth up to Euro 1 billion between February and December 2026, reinforcing its capital allocation strategy and long-term growth outlook.
Biopharmaceutical Company | 04/02/2026 | By News Bureau | 212
Andera Partners participated in Exciva’s Euro 51 million Series B round to advance Deraphan into Phase II trials for agitation in Alzheimer’s disease across Europe and North America.
Biopharmaceutical Company | 23/01/2026 | By News Bureau
GSK will acquire RAPT Therapeutics for USD 2.2 billion, adding phase IIb anti-IgE antibody ozureprubart to its pipeline, targeting long-acting protection for patients with severe food allergies.
Biopharmaceutical Company | 20/01/2026 | By News Bureau | 166
AstraZeneca Acquires Full Global Rights to AbelZeta's CAR-T Therapy C-CAR031 in USD 630 Million Deal
AstraZeneca has acquired AbelZeta Pharma’s China rights to CAR-T therapy C-CAR031 for up to USD 630 million, securing full global development and commercialisation rights for the liver cancer treatment.
Biopharmaceutical Company | 20/01/2026 | By News Bureau | 115
European Commission Approves Sobi's Aspaveli for Rare Kidney Diseases C3G and IC-MPGN
The European Commission has approved Sobi’s Aspaveli for adolescents and adults with rare kidney diseases C3G and IC-MPGN, marking the first approved therapy for these conditions.
Biopharmaceutical Company | 19/01/2026 | By News Bureau | 160
Harbour BioMed has exercised its warrant to acquire shares in Spruce Biosciences, securing a 3.8 percent stake and deepening their collaboration to advance SPR202 for rare endocrine and immune disorders.
Biopharmaceutical Company | 19/01/2026 | By News Bureau | 144
Prokaryotics, Basilea Partner to Develop First-in-Class Broad-Spectrum Antifungal
Partnership between Prokaryotics and Basilea will develop broad-spectrum antifungal treatment that targets life-threatening invasive fungal infections.
Biopharmaceutical Company | 07/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy